Recent Updates — ADIL
Adial Pharmaceuticals convened its 2026 Annual Meeting on September 17, 2026, where stockholders approved director elections for Cary J. Claiborne and Robertson H. Gilliland, the ratification of CBIZ CPAs P.C. as auditor, an increase in authorized common shares from 100 million to 500 million, and new equity incentive plans. The meeting was adjourned regarding proposals requiring Nasdaq Listing Rule 5635(d) compliance until October 1, 2026, pending conditional exchange approval. Adial Pharmaceuticals is a biopharmaceutical company focused on developing treatments for central nervous system disorders.
Adial Pharmaceuticals amended its Securities Purchase Agreement and Note Exchange Agreements to remove a penalty provision, reclassifying milestone warrant rights from liability to equity. This change restores compliance with Nasdaq Capital Market listing requirements by increasing stockholders' equity above the minimum threshold. The pro forma balance sheet shows total assets of $29.1 million and total liabilities of $6.2 million as of June 30, 2026. Adial Pharmaceuticals operates in the biopharmaceutical industry.
Adial Pharmaceuticals received a notice from Nasdaq on August 18, 2026, indicating it no longer satisfies the minimum stockholders' equity requirement of $2.5 million for continued listing under Rule 5550(b)(1). The company also lacks alternative quantitative standards regarding market value or net income. Adial has until October 2, 2026, to submit a compliance plan and may seek an extension of up to 180 days if the plan is accepted. The firm anticipates regaining compliance by converting its Series A Non-Voting Convertible Preferred Stock upon shareholder approval at the 2026 Annual Meeting. Adial Pharmaceuticals operates in the biopharmaceutical industry, developing treatments for central nervous system disorders.
Adial Pharmaceuticals reported second quarter 2026 financial results and announced the completed acquisition of Azora Therapeutics, adding AT177, an oral AhR agonist for ulcerative colitis, to its pipeline. The company closed the initial $32 million tranche of a $64 million private placement, which included the conversion of $5.5 million in notes. Cash and cash equivalents rose to $28.7 million from $4.6 million at the end of March 2026. The quarter ended June 30, 2026, resulted in a net loss of $52.0 million, or $(11.25) per share, driven primarily by a $46.2 million non-cash charge for acquired in-process research and development expenses related to the Azora transaction. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases.
Adial Pharmaceuticals announced that its current President and CEO Cary Claiborne and CFO Vinay Shah will be terminated effective after the September 17, 2026 Annual Meeting if specific stockholder proposals are approved. Upon termination, they will receive severance per their employment agreements. Chief Development Officer Matthew Davidson is slated to become President and CEO, with a new CFO to be appointed. The filing also sets the annual meeting date for September 17, 2026, and establishes August 23, 2026 as the deadline for stockholder proposals. This corporate governance restructuring involves significant leadership changes contingent on shareholder approval at an upcoming vote. Adial Pharmaceuticals operates in the pharmaceutical industry, focusing on developing treatments for gastrointestinal disorders.